Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.65 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22281 | 0.89 | PARP10 (0.78) | TSHRSRD5A2PARP15PARP10CA1 | |
| SCHEMBL5581520 | 0.89 | PARP10 (0.78) | TSHRSRD5A2PARP15PARP10CA1 | |
| Terephthalic Acid SCHEMBL9861713 | 0.89 | PARP10 (0.78) | TSHRSRD5A2PARP15PARP10CA1 | |
| SCHEMBL766069 | 0.89 | PARP10 (0.78) | TSHRSRD5A2PARP15PARP10CA1 | |
| SCHEMBL7822703 | 0.88 | POLB (0.66) | TSHRALOX15SRD5A2PARP15PARP10 | |
| SCHEMBL20805848 | 0.86 | FAAH (0.67) | TSHRALOX15CA1CA2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9436485 | 0.86 | PARP10 (0.75) | TSHRSRD5A2PARP15PARP10CA1 | |
| Hydrochloric Acid SCHEMBL9633355 | 0.86 | PARP10 (0.75) | TSHRSRD5A2PARP15PARP10CA1 | |
| Hydrochloric Acid SCHEMBL5042789 | 0.86 | PARP10 (0.75) | TSHRSRD5A2PARP15PARP10CA1 | |
| Hydrochloric Acid SCHEMBL2709951 | 0.86 | PARP10 (0.75) | TSHRSRD5A2PARP15PARP10CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| WO-2025104079-A1 | SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-05-22 | — | — | WO | disclosed |
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-111868055-B | Inhibitors of TRPC6 | 勃林格殷格翰国际有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
| WO-2003087046-A1 | NOVEL AMINOTETRALINE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087044-A2 | NOVEL CARBOXAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087045-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
| EP-0273418-B1 | Heat-sensitive recording material using chromeno compound | KANZAKI PAPER MFG CO LTD (JP) | 1993-11-24 | — | — | EP | disclosed |
| US-5034410-A | Nitrile and oxo containing amides or thioamides | SYNTEX (U.S.A.) INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4803193-A | COLORFASTNESS; READABLE BY OPTICAL CHARACTER-READING DEVICES | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| EP-0273418-A2 | Heat-sensitive recording material using chromeno compound | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1988-07-06 | — | — | EP | disclosed |
| US-4460400-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |
| US-4247682-A | DOUBLE ENDCAPPING BY AN ELECTROPHILIC AND A NUCLEOPHILIC END GROUP OF A POLYMER PREPARED BY AN ELECTRONEGITIVELY SUBSTITUTED AROMATIC ACID HALIDE OR SULFONYL HALIDE; MOLECULAR WEIGHT CONTROL; HEAT RESISTANCE | RAYCHEM CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | TSHR 3129/4885ALOX15 7/4885SRD5A2 392/4885 |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | TSHR 1986/4885ALOX15 2065/4885SRD5A2 3477/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | TSHR 15/4885ALOX15 2350/4885SRD5A2 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.